By Dimitra Sotou, Senior Consultant, Pricing & Market Access Day 1 of official lockdown today, and increasingly more organizations around the globe are facing tighter operational restrictions due to the COVID-19 outbreak – Name it: day-to-day work, restricted travel, team meetings, cancelled conferences,…
We hope you are all safe and in good health. At GPI, we are extremely proud to present our new offering, GPI HORIZON, an innovative methodology supporting early price and access forecasting. Despite the uncertainty and change brought by COVID-19 outbreak, GPI have…
Pricing & Market Access leader enhances pricing database with world’s leading analytics platform for technology developers London, UK, March 17, 2020 – Global Pricing Innovations (GPI), a leader in analytical market access solutions for biopharma, has announced the Spring 2020 release of new features…
Author – Nairuti Patel (Associate Consultant, GPI) On 3rd March 2020, the Spanish Council of Ministers announced a ‘specific pricing system’ for orphan medicinal product that will be separate from the reference pricing system. The reference pricing system applies to all other products reimbursed by the Spanish National Health System (SNS) when their patent has expired. The only instance when orphan drugs will be included in this new…
At the end of 2019, important legislative changes took place in the United States that could impact the country’s pharmaceutical industry over the coming years. The U.S. House of Representatives has passed the Lower Drug Costs Now Act on 12th December 2019, setting…
By Pramod Kumar Mali, Senior Business Analyst Back in August 2019, GPI reported the new regulations finalized by Canada to tackle high drug prices by making amendments to the Patented Medicines Regulations. On November 21, 2019, the Patented Medicines Prices Review Board (“PMPRB”)…
